Pancreatic Cancer Research

Clinical trialPhase 2Completed

RP-6306 in Patients With Advanced Cancer

A Phase II Study of RP-6306 in Patients With Advanced Cancer

Outcome
Finished, no results posted
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
24 May 2023
Ended
5 February 2026
Enrollment
28 participants
Sites
6
Primary outcomes
Response rate of RP-6306 in patients with selected cancers receiving standard agent
Sponsor type
Network
Results posted
No
Last update
6 February 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study is being done to answer the following questions: * Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment? * If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.

Detailed description public domain (ClinicalTrials.gov)

RP-6306 is a PKMYT1 inhibitor. PKMYT1 protein kinase negatively regulates CDK1 via phosphorylation of threonine 14 (Thr14) and sequestration in the cytoplasm. RP-6306 has shown single-agent anti-tumour efficacy in several xenograft models with amplified CCNE1 in a dose-dependent manner. RP-6306 has synergistic effects in combination with gemcitabine in CCNE1-amplified/overexpressing models in vitro and in vivo